Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy

Inclusion Criteria: * Admitted to the Hospital of the University of Pennsylvania (HUP) in the past 72 hours. * Current HUP locations are Founders 12, Founders 14, Silverstein 11, and Rhoads 1. * Age 18 years or older. * Type-1 or type-2 diabetes mellitus requiring home basal-bolus insulin therapy administered via subcutaneous injection (not pump). * Patient manages own basal-bolus insulin therapy at home without assistance, including measuring own blood glucose (at least at mealtimes) and administering own subcutaneous insulin. * Patient is willing to use the following insulin products: rapid-acting insulin aspart via insulin pen (NovoLog) and long-acting insulin glargine via vial and syringe (Lantus). * Most recent hemoglobin A1c was measured within past 6 months and was \<7.5%. * Active order for in-hospital basal-bolus or sliding-scale insulin. * Patient is willing and able to record their self-measured blood glucose results, doses of insulin that they self-administer, a food journal, and exercise log. * Clinical care team agrees with study inclusion. Exclusion Criteria: * Inpatient order for insulin via subcutaneous infusion (i.e., pump) or intravenous infusion (i.e., drip). * Inability to perform the activities required by the trial. * Primary reason for admission was hyperglycemia, hypoglycemia, diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma, a psychiatric condition, acute alcohol poisoning, or acute drug ingestion. * Order for a newly-prescribed or increased dose of a previously-prescribed corticosteroid. * Enteral or parenteral nutrition. * Expected length of stay \<48h, as determined by treating physician. * At risk for self-harm, as determined by 1-to-1 status placement. * Pregnant, as recorded on medical record. * Cannot understand, speak, and read English. * Patient does not wish to utilize Novolog and Lantus while in the hospital. * Prior enrollment in this trial. * Do not resuscitate status. * Inability to give written informed consent. * Clinical care team disagrees with study inclusion. * Patient has limited mobility such that they cannot safely access the bedside medication lockbox.